Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.04% | -27.42% | -30.31% | -5.06% | -3.03% |
| Total Depreciation and Amortization | -3.33% | 1.12% | 9.88% | 6.58% | 35.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.61% | 56.86% | 1.66% | 13.12% | 6.29% |
| Change in Net Operating Assets | -145.25% | 245.15% | -23.65% | -277.42% | 57.54% |
| Cash from Operations | -25.36% | 18.80% | -33.12% | -42.73% | 2.42% |
| Capital Expenditure | 100.00% | 66.27% | 63.76% | -222.54% | 86.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.53% | -- | 100.00% | -1,666.30% | 202.06% |
| Cash from Investing | 28.73% | 22,562.65% | 99.89% | -1,692.54% | 190.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 33.29% | 0.00% | 0.00% |
| Issuance of Common Stock | 966.67% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -228.00% | 142.02% | -- | -- | -- |
| Cash from Financing | -100.00% | 107.53% | -100.80% | 10,764.95% | -404.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.39% | 174.22% | -314.19% | 381.66% | 81.92% |